MARKET NEWS

Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide
Ajinomoto Althea Celebrates 20 Years in San Diego & Opening of New Facility
Gerresheimer Gx Solutions Developing Packaging Solutions for Complex Injectable Drugs of Tomorrow
UPM Pharmaceuticals Appoints New Director of Analytical Development
Global Contract Research Organization Announces $7.8-Million Extension Agreement
Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy

  FEATURED EDITORIAL

  COMPANY PROFILE

Pfizer CentreOne is a global contract manufacturer that focuses on API synthesis, sterile injectables fill-finish and highly potent solids. For more than 40 years, we’ve manufactured complex compounds for our biopharmaceutical partners. Our dedicated team of contract manufacturing experts guide your drug safely from development through commercialization, backed by the quality and resources of Pfizer. Our company was born of the September 2015 union of Pfizer CentreSource, a global leader in specialty APIs, and Hospira One 2 One, one of the world’s premier sterile-injectables CMOs. As a combined organization, we’ve brought together the best of our manufacturing capabilities to provide a wider array of services and technologies to our biopharmaceutical partners. Although Pfizer CentreOne is a new name, we’re not new to the industry, with more than 40 years of contract manufacturing experience. Click here for more.

  EXCLUSIVE ONLINE CONTENT

SunGen Pharma Establishes Injectable Division, Form­s Manufacturing Relationship

SunGen Pharma Establishes Injectable Division, Form­s Manufacturing Relationship

SunGen Pharma recently announced it has entered into a Manufacturing Agreement with Grand River Aseptic Manufacturing (GRAM) to manufacture generic injectable pharmaceutical products.

Cynata’s Stem Cell Therapy Meets All Safety & Efficacy Endpoints in Trial

Cynata’s Stem Cell Therapy Meets All Safety & Efficacy Endpoints in Trial

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited recently announced that CYP-001, its lead Cymerus mesenchymal stem cell (MSC) product candidate, met all clinical endpoints in a Phase 1 trial for the treatment of steroid-resistant acute graft-versus-host disease (GvHD).

Emergent BioSolutions to Acquire ADAPT Pharma

Emergent BioSolutions to Acquire ADAPT Pharma

ADAPT Pharma recently announced it has entered into a definitive agreement to be acquired by Emergent BioSolutions. Adapt is solely focused on helping address the opioid overdose and addiction crisis.

Pfizer, Astellas

Pfizer & Astellas Amend Clinical Research Protocols for Two Phase 3 Trials

Pfizer Inc. and Astellas Pharma Inc. recently announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).

ImmunoBiochem

CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies

The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB provide a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 12 – Injection Devices
September 19 – Lyophilization Manufacturing